Xilio Therapeutics, Inc.
XLOAs of the close on Sep 25, 2026
Price
$9.04
Market cap
$52.3M
P/E (diluted TTM)
—
Not meaningful: the last four quarters were a loss
EPS (TTM)
−$1.74
Four quarters to Jun 30, 2026
Dividend yield
—
Dividend records do not yet cover the latest payments
Figures shown here come from public SEC filings. Dates beside each section show the available history.
How Xilio Therapeutics, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 6 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 12, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 2026-03-31 | 650,389 | $5.47M | SEC filing |
| UBS Group AG | 2025-12-31 | 203 | $130 | SEC filing |
| Pinnacle Financial Group, LLC / IL | 2025-12-31 | 10,000 | $6.4K | SEC filing |
| CITADEL ADVISORS LLC | 2025-12-31 | 436,216 | $279K | SEC filing |
| XTX Topco Ltd | 2025-12-31 | 17,304 | $11.1K | SEC filing |
| STEMPOINT CAPITAL LP | 2025-12-31 | 2,030,028 | $1.3M | SEC filing |
| AJU IB Investment Co., Ltd. | 2025-12-31 | 667,742 | $427K | SEC filing |
| GILEAD SCIENCES, INC. | 2025-12-31 | 9,105,451 | $5.83M | SEC filing |
| Key Financial Inc | 2025-12-31 | 830 | $531 | SEC filing |
| GSA CAPITAL PARTNERS LLP | 2025-12-31 | 147,966 | Not shown | SEC filing |
| Dunhill Financial, LLC | 2025-12-31 | 10,274 | $6.58K | SEC filing |
| Mariner, LLC | 2025-12-31 | 25,000 | $16K | SEC filing |
| HRT FINANCIAL LP | 2025-12-31 | 31,886 | Not shown | SEC filing |
| RENAISSANCE TECHNOLOGIES LLC | 2025-12-31 | 344,416 | $220K | SEC filing |
| LPL Financial LLC | 2025-12-31 | 21,000 | $13.4K | SEC filing |
| MORGAN STANLEY | 2025-12-31 | 839,850 | $538K | SEC filing |
| BANK OF AMERICA CORP /DE/ | 2025-12-31 | 261 | $167 | SEC filing |
| Bain Capital Life Sciences Investors, LLC | 2025-12-31 | 7,372,686 | $4.72M | SEC filing |
| Frazier Life Sciences Management, L.P. | 2025-12-31 | 5,915,091 | $3.79M | SEC filing |
| VANGUARD GROUP INC | 2025-12-31 | 1,255,692 | $804K | SEC filing |
- Each value is checked against Xilio Therapeutics, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 2 rows: the filed value is about 1,000 times too small for the share count at Xilio Therapeutics, Inc.'s share price.
Filer report history
Two reports per filer, as filed. No change is calculated, because the data on file cannot confirm that both reports describe the same security.
- GILEAD SCIENCES, INC.: 9,105,451 shares reported 2025-12-31; 650,389 shares reported 2026-03-31.
- GILEAD SCIENCES, INC.: 9,105,451 shares reported 2025-09-30; 9,105,451 shares reported 2025-12-31.
- Merck & Co., Inc.: 1,483,758 shares reported 2025-09-30; 1,483,758 shares reported 2025-12-31.
- BlackRock, Inc.: 2,037 shares reported 2025-09-30; 2,037 shares reported 2025-12-31.
- INVESTORS ASSET MANAGEMENT OF GEORGIA INC /GA/ /ADV: 10,000 shares reported 2025-09-30; 10,000 shares reported 2025-12-31.
- GEODE CAPITAL MANAGEMENT, LLC: 328,972 shares reported 2025-09-30; 328,972 shares reported 2025-12-31.
- BRIDGEWAY CAPITAL MANAGEMENT, LLC: 56,081 shares reported 2025-09-30; 56,081 shares reported 2025-12-31.
- STATE STREET CORP: 163,890 shares reported 2025-09-30; 186,390 shares reported 2025-12-31.
- TWO SIGMA INVESTMENTS, LP: 87,790 shares reported 2025-09-30; 62,032 shares reported 2025-12-31.
- RAYMOND JAMES FINANCIAL INC: 18,761 shares reported 2025-09-30; 18,761 shares reported 2025-12-31.
- Private Wealth Management Group, LLC: 310 shares reported 2025-09-30; 310 shares reported 2025-12-31.
- NORTHERN TRUST CORP: 66,609 shares reported 2025-09-30; 66,609 shares reported 2025-12-31.
Showing the 12 most recent filer reports.
17 filers have only one report here.
Independent insiders buying near the same time
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-03-26 | Shannon James Samuel · Director | Common Stock | P — Open market or private purchase | +5,000 | 8.79 | SEC filing |
| 2026-02-13 | GILEAD SCIENCES, INC. · 10% owner | Prefunded Warrants (right to buy) | P — Open market or private purchase | +3,739,000 | 0.53 | SEC filing |
| 2026-01-02 | Frankenfield Christopher James · Chief Financial Officer | Common Stock | S — Open market or private sale | −7,030 | 0.64 | SEC filing |
| 2026-01-02 | Brennan Kevin M. · SVP, FINANCE AND ACCOUNTING | Common Stock | S — Open market or private sale | −1,826 | 0.64 | SEC filing |
| 2025-06-17 | Shannon James Samuel · Director | Common Stock | P — Open market or private purchase | +25,000 | 0.69 | SEC filing |
| 2025-06-16 | Russo Rene · PRESIDENT AND CEO | Common Stock | P — Open market or private purchase | +36,289 | 0.68 | SEC filing |
| 2025-06-16 | Shannon James Samuel · Director | Common Stock | P — Open market or private purchase | +45,000 | 0.69 | SEC filing |
| 2025-06-05 | GILEAD SCIENCES, INC. · 10% owner | Prefunded Warrants (right to buy) | P — Open market or private purchase | +13,335,000 | unknown | SEC filing |
Showing 8 of 20 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-11 | Bello Akintunde Olatokumbo · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +5,000 | SEC filing |
| 2026-06-11 | Bonstein Sara · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +5,000 | SEC filing |
| 2026-06-11 | Brennan Aoife · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +5,000 | SEC filing |
| 2026-06-11 | Curran Daniel J. · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +5,000 | SEC filing |
| 2026-06-11 | Shannon James Samuel · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +5,000 | SEC filing |
| 2026-06-11 | Xu Yuan · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +5,000 | SEC filing |
| 2026-06-11 | ROSS ROBERT W. · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +5,000 | SEC filing |
| 2026-04-15 | Blanchard Cheryl R · Director | Stock Option (right to buy) | A — Grant, award, or other acquisition | +10,000 | SEC filing |
Showing 8 of 20 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2025-11-21 | Luptakova Katarina · CHIEF MEDICAL OFFICER | Stock Option (right to buy) | D — Disposition to the issuer | −15,000 | SEC filing |
| 2025-11-21 | Russo Rene · PRESIDENT AND CEO | Stock Option (right to buy) | D — Disposition to the issuer | −700,000 | SEC filing |
| 2025-11-21 | Luptakova Katarina · CHIEF MEDICAL OFFICER | Stock Option (right to buy) | D — Disposition to the issuer | −106,000 | SEC filing |
| 2025-11-21 | Frankenfield Christopher James · Chief Financial Officer | Stock Option (right to buy) | D — Disposition to the issuer | −150,000 | SEC filing |
| 2025-11-21 | Frankenfield Christopher James · Chief Financial Officer | Stock Option (right to buy) | D — Disposition to the issuer | −117,000 | SEC filing |
| 2025-11-21 | Frankenfield Christopher James · Chief Financial Officer | Stock Option (right to buy) | D — Disposition to the issuer | −155,090 | SEC filing |
| 2025-11-21 | Russo Rene · PRESIDENT AND CEO | Stock Option (right to buy) | D — Disposition to the issuer | −135,134 | SEC filing |
| 2025-11-21 | Russo Rene · PRESIDENT AND CEO | Stock Option (right to buy) | D — Disposition to the issuer | −473,334 | SEC filing |
Showing 8 of 10 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.